Liminatus Pharma Raises $650K in Private Placement Deal

Liminatus Pharma, Inc. has entered into a subscription agreement for a private placement of its common stock with a non-U.S. investor. The agreement entails the issuance of 260,001 shares at $2.50 per share, generating aggregate gross proceeds of $650,002.50. The company plans to utilize these net proceeds for working capital and general corporate purposes. The shares are being offered in reliance on exemptions from registration under the Securities Act of 1933. The private placement is anticipated to close on or about November 20, 2026, and the company has agreed to file a registration statement for resale within 60 days of closing.